https://www.prognyx.com/blog/galleri-s-randomized-endpoint-came-back-at-1-03-and-an-fda-advisory-committee-isPrognyxen2026-08-07Galleri's randomized endpoint came back at 1.03 — and an FDA advisory committee is reported for September https://www.prognyx.com/blog/two-phase-3s-target-low-intensity-follicular-lymphoma-standards-surovatamig-vs-rPrognyxen2026-08-06Two Phase 3s target low-intensity follicular lymphoma standards: surovatamig vs radiotherapy, mosunetuzumab vs rituximab